Novartis’ Mayzent® (siponimod) is one of the first drugs to be approved for...
Retrophin’s fosmetpantotenate fails in Phase III trial for PKAN
Biopharmaceutical firm Retrophin has reported that the Phase III clinical trial of fosmetpantotenate failed to meet endpoints in pantothenate kinase-associated neurodegeneration (PKAN) patients.
Zolgensma and Spinraza may face spinal muscular atrophy market shortfall
Spinraza and Zolgensma are involved in ongoing clinical trials in presymptomatic treatment of spinal muscular atrophy patients, providing stronger evidence for physicians to recommend using these treatments.
Biohaven completes patient enrolment in rimegepant trial for migraine
Biohaven Pharmaceutical has completed patient enrolment in its pivotal Phase III trial of rimegepant as a preventive treatment for migraine.
Lilly reports positive data from CONQUER study of Emgality
Eli Lilly and Company has reported positive data from the Phase III CONQUER study of Emgality (galcanezumab-gnlm) in patients who failed previous migraine preventive treatments.
AAV gene therapy shows positive results in Batten disease trial
Amicus Therapeutics has announced interim data from a Phase I/II clinical trial of an AAV gene therapy for the treatment of CLN6 Batten disease in children.
Biohaven initiates enrolment in verdiperstat’s study for MSA
Biohaven Pharmaceutical has started patient enrolment in a Phase III clinical trial being conducted to assess verdiperstat for the treatment of multiple system atrophy (MSA).
Alkermes-Biogen’s MS drug shows improved GI tolerability
Alkermes and Biogen have reported that diroximel fumarate demonstrated a statistically superior gastrointestinal (GI) tolerability profile compared to Tecfidera (dimethyl fumarate) in a Phase III EVOLVE-MS-2 study for relapsing-remitting multiple sclerosis (RRMS).
Oryzon closes enrolment in vafidemstat’s Phase IIa trials
Spain-based Oryzon Genomics has completed patient enrolment in the Phase IIa REIMAGINE and REIMAGINE-AD clinical trials of vafidemstat.
Janssen’s ponesimod meets primary endpoint in OPTIMUM trial
Janssen Pharmaceutical has reported top-line data from the Phase III OPTIMUM clinical trial of ponesimod in relapsing multiple sclerosis patients, revealing that the study met its primary endpoint.
Acadia reports mixed results for schizophrenia drug in trial
Acadia Pharmaceuticals has reported top-line data from the Phase III ENHANCE clinical trial of its pimavanserin drug to treat schizophrenia in adults with persistent inadequate response to current therapy.